ReviewCancer immunology, immunotherapy : CII2007
CD4 regulatory T cells in human cancer pathogenesis.
Review in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00726037 (A Pilot Study Evaluating the Efficacy of Regulatory T-cell), which is not on this map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer
Who cites it
61 citing papers in PubMed, 114 citations in OpenAlex.
- Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.Journal of immunology (Baltimore, Md. : 1950) · 2012Trial
- Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.Cancer prevention research (Philadelphia, Pa.) · 2010Trial
- Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.Discover oncology · 2026Article
- Orchestrating the pre-metastatic niche: roles of stromal mediators and immune cells in metastatic progression and therapeutic targeting.Frontiers in immunology · 2026Review
- Stem-like CD4 T cells in tumors: an emerging framework for antitumor immunity.Frontiers in immunology · 2026Review
- Cyanidin-3-O-glucoside-mediated reduction of regulatory T cells: a therapeutic strategy for multiple myeloma.BMC immunology · 2025Article
- Clinical and immunological characteristics of high-risk double-hit multiple myeloma.BMC cancer · 2024Article
- Immune mediated support of metastasis: Implication for bone invasion.Cancer communications (London, England) · 2024Review
- What happens to regulatory T cells in multiple myeloma.Cell death discovery · 2023Review
- Immune checkpoint analysis in ear cancer.Head & face medicine · 2023Article
- Effects of pre-operative biopsy on recurrence and survival in stage I lung adenocarcinoma patients in China.ERJ open research · 2023Article
- Oncogenic Viruses-Encoded microRNAs and Their Role in the Progression of Cancer: Emerging Targets for Antiviral and Anticancer Therapies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3BMC gastroenterology · 2022Article
- Review
- Immunological Prognostic Factors in Multiple Myeloma.International journal of molecular sciences · 2021Review
- T-Regulatory Cells In Tumor Progression And Therapy.Cancer management and research · 2019Review
- Melatonin and Hippo Pathway: Is There Existing Cross-Talk?International journal of molecular sciences · 2017Article
- Immunotherapy of advanced renal cell carcinoma: Current and future therapies.Human vaccines & immunotherapeutics · 2016Review
- Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Cancer metastasis reviews · 2016Review
- Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.Targeted oncology · 2016Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4(+) T cell lineage (i.e., CD4(+) Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4(+) Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body's immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4(+) Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.